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& p . 1 :Abstract Pharmacological characterization of ion
channels and receptors in cultured neurons or transfec-
ted cell lines requires microapplication of multiple drug
solutions during electrophysiological recording. An
ideal device could apply a large number of solutions to
a limited area with rapid arrival and removal of drug
solutions. We describe a novel “multipuffer” rapid ap-
plication device, based on a modified T-tube with a
nozzle made from a glass micropipette tip. Drug solu-
tions are drawn via suction from open reservoirs
mounted above the recording chamber through the de-
vice into a waste trap. Closure of a solenoid valve be-
tween the device and the waste trap causes flow of drug
solution though the T-tube nozzle. Any number of drug
solutions can be applied with rapid onset (50–100 ms)
after a brief fixed delay (100–200 ms). Recombinant
α1β1γ2S GABAA receptors (GABARs) transfected into
L929 fibroblasts were recorded using whole-cell and
single-channel configurations. Application of GABA
resulted in chloride currents with an EC50 of 12.2 µM
and a Hill slope of 1.27, suggesting more than one
binding site for GABA. GABAR currents were en-
hanced by diazepam and pentobarbital and inhibited by
bicuculline and picrotoxin. Single-channel recordings
revealed a main conductance state of 26–28 pS. This
device is particularly suitable for rapid, spatially con-
trolled drug applications onto neurons or other cells re-
corded in the whole-cell configuration, but is also ap-
propriate for isolated single-channel or multichannel
membrane patch recordings.
& k w d :Key words Drug application · Superfusion ·
GABAA receptor · Ion channel · Electrophysiology ·
Pharmacological technique& b dy :
Introduction
Microapplication of drug solutions to cells in culture dur-
ing electrophysiological recording has been a vexing
problem for neurophysiologists. An ideal drug applica-
tion system would provide rapid onset of solution change,
instantaneous shift to a constant drug concentration, rapid
washout of drug after application, no additional superfu-
sion or drain requirements and an unlimited ability to
change solutions. Pressure ejection of drug solutions from
single or multibarrel pipettes pulled to small tip openings
(10–20µm) can rapidly deliver a drug solution to a local-
ized area, but this technique is limited to application of a
single drug concentration per pipette barrel. More recent-
ly, the U-tube or T-tube approach has been used to apply
multiple drug concentrations [22]. In this system, fluid is
sucked through a U-shaped tube past a small opening (or
perpendicular “T”-tube) until flow is is abruptly terminat-
ed by closure of a solenoid valve. Fluid is then forced out
the U-tube or T-tube opening by gravity. Advantages of
this system include relatively fast onset of solution
changes and delivery of a uniform drug concentration, as
well as potentially unlimited drug concentrations. Disad-
vantages include the inability to apply drugs to a limited
region of the dish (to minimize desensitization of recep-
tors on other cells), and the larger volume of applied drug
requires simultaneous superfusion with saline and a drain
system, which may add noise to the recording.
To address these problems, we have developed a nov-
el device, the “multipuffer”, which combines the tip of a
glass puffer pipette (allowing precise control of the loca-
tion and volume of application) with a T-tube (for rapid
uniform drug concentration). Addition of the puffer tip
reduces the superfused volume and allows precise con-
trol of location, but lengthens the delay between solenoid
closure and drug application. The “T-tube” is incorporat-
ed into an acrylic holder fitted with a metal tube over
which a glass micropipette tip is fitted and secured with
an O-ring. Application of drug thus occurs through the
fine tip of a glass micropipette. This device allows any
number of drug solutions to be applied though the same
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pipette tip to a small area of a culture dish with fairly
rapid solution exchange. This enables the experimenter
to apply a whole range of drug solutions or concentra-
tions during an experiment, and to change or add drug
concentrations during a recording. The tip of the device
can be placed very close to the cell or patch of interest,
and need not be removed between applications. As the
position of the device does not change during a record-
ing, drug applications are more accurate and consistent.
Drug solutions are “washed away” by the sucking action
of the device between applications of drug, which mini-
mizes problems of drug desensitization. The small vol-
ume of solution applied obviates the need for simulta-
neous superfusion and drainage systems, and the ability
to cycle quickly among multiple drugs, in any order,
makes each experiment more likely to yield useful data.
We have used this device to characterize the whole-
cell and single-channel pharmacology of recombinant
GABAA receptors (GABARs) in transfected L929 cells
[4, 9, 15, 16, 27], native GABARs in cortical neurons in
primary culture [14], and in acutely isolated hippocam-
pal dentate granule cells [13]. In this study, we examined
the kinetics of the drug application system and the result-
ing effects on recombinant GABAR currents.
Materials and methods
Multipuffer drug application system
The multipuffer application device consists of a “head piece” made
from a length of 9.53 mm (3/8″) diameter acrylic rod, with the “U-
tube” solution passage drilled into the block (see Fig. 1A). The
“cross tube” (i.e., the bottom of the “U”) must be drilled through
the side of the block and the opening plugged with a glued insert.
The front end of this head piece is drilled with recesses for the back
end of the pipette tip and the O-ring that secures it. A fine hole is
drilled through the center of the pipette recess into the “cross tube”
of the U-tube, and a piece of steel tubing is pressed or glued into
this hole. The O-ring and pipette tip are secured with an acrylic cap
that screws over the headpiece, tightening down on the O-ring to
form an air-water-tight seal and to secure the pipette tip in place.
The back end of the head piece has stainless steel tubes inserted in-
to the U-tube holes for attaching polyethylene tubing (Intramedic
PE 190, Clay Adams, Persippany, N.J., USA). The head piece is
held by a rigid plastic tube that is attached to a micromanipulator
(eg. Brinkman, Leitz, etc.). The polyethylene tubing from the head
piece passes out the open end of the plastic support tube and is con-
nected to the valve manifold (the source of drug solutions) and to
the solenoid valve, which in turn is connected to the vacuum flask.
A short length of compressible (eg. Tygon) tubing is used to make
these connections, so that a pressure clamp can be used to stop the
flow of drug solutions when appropriate.
Drugs solutions are stored in open plastic (Corning or Falcon)
or glass (Pyrex) 50-ml tubes in a test tube rack suspended on a
ringstand at a fixed height above the microscope stage (generally
20–40 cm depending on the rate of flow desired). Four polyethyl-
ene “feed” tubes (PE 190) pass from the open drug reservoirs to a
manifold (Hamilton HV PD4-5 manual valve) to select which drug
solution flows to the device. Feed tubes can be moved from one so-
lution to the next by hand, obviating the need for a valve position
for each solution. The “drain end” of the multipuffer tubing is con-
nected to a solenoid valve [General Valve 3 way 12 V Teflon mem-
brane valve no. 1–17–900 or Cole Parmer (Niles, Ill., USA) CP no.
01367–72, mounted in “normally open” configuration]. The sole-
noid valve is actuated by a Valve Driver II (General Valve, Fair-
field, N.J., USA) controlled by a Repeat Cycle Timer (Lafayette In-
strument, Lafayette, Ind., USA). Nominal closing time for these
valves is 8–15 ms. The solenoid valve is then connected to a vacu-
um pump [e.g., modified “Supra” or larger fish tank pump (Second
Nature)] or other source of vacuum via a solution trap (1- to 2-l
vacuum flask). While we have minimized costs by using a manual
switching valve and a standard interval timer, more elaborate con-
trol could be achieved by using a computer to control both an elec-
tronic mechanized manifold valve and the solenoid. The configura-
tion of the drug reservoirs, manifold, multipuffer device, solenoid,
a d vacuum trap is shown in Fig. 1B. Placement flexibility is great-
est when the device is used with an inverted microscope.
A critical element in the function of the device is the glass pi-
pette tip. We have used Pyrex glass tubes (Drummond Custom
Glass N-51-A) with inside diameter (I.D.) of 0.6 mm and outside
diameter (O.D.) of 1.2 mm, pulled to a tip diameter of 30–70µm
using a P-87 Flaming Brown Microelectrode Puller (Sutter Instru-
ment). The type of glass is unimportant, though microelectrode
glass with an internal glass filament should not be used, as the fila-
ment tends to fracture when placed on the holder and the glass
fragments can plug the tip or be sucked back to the solenoid where
they can puncture the Teflon membrane of the valve. The distal
1 cm or so of the pulled pipette tip can be broken cleanly from the
remainder of the electrode shaft after scoring with a diamond pen.
The tip is then placed on the assembled holder and pushed through
the O-ring and the screw cap tightened to hold the tip in place. It is
ssential to cut the tip off at a length long enough to have the open
end well seated in the device and clamped by the O-ring, but short
enough that the metal insert comes to the beginning of the tip taper.
When a drug is to be applied, the appropriate feed tube is se-
lected with the 4:1 manifold valve. After 5–10 s (to allow the drug
solution to pass into the multipuffer), the solenoid is activated for
a predetermined interval. When the solenoid valve closes, the vac-
uum stops and solution flows via gravity from the drug reservoir
out the multipuffer tip onto the region of interest. The rate of solu-
tion application and the delay between solenoid activation and ar-
rival of drug depend directly on the diameter of the glass pipette
tip. Pipettes pulled to a internal tip diameter of about 50–70µm
allow fast enough flow to give onsets within 100–200 ms of sole-
noid closure without “blowing away” the cell or patch (see Fig. 2).
Smaller openings give more spatially controlled applications but
longer onset delays and increased mixing of drug with saline from
the recording bath.
Under most experimental conditions with tip configurations
used, the rates of solution flow are well below those normally asso-
ciated with generation of turbulence. The onset of turbulent flow
can be predicted by the Reynold number, RN, given by the equation:
RN = 2ρau/η (1)
where ρ is the fluid density, u is the linear fluid velocity, a is the
radius of the capillary tube, and η is the viscosity (in g·m–1·s–1, or
Poise, where 1 cp = 1 mNs/m2). Onset of turbulence is generally
associated with an RN greater than 2000. The values of ρ and η for
a dilute solution can be approximated by those for water
(ρ = 1.00 g/cm3, η = 1.009 cP ≈0.01 g·cm–1·s–1), while the linear
velocity can be determined from the delay between solenoid actu-
ation and solution change, since the applied solution travels a
fixed distance down the length of the T-tube to the electrode tip.
For a delay of 100 ms (seen with application of a KCl solution to
an “open” electrode through a glass capillary tip opening of 60µm
diameter) and a travel distance of 1.0 cm, the velocity would be
10 cm/s. The calculation of RN is thus:
RN = 2·(1.00 g·cm–3)·(3·10–3cm)·(10 cm·s–1)/(0.01 g·cm–1·s–1) = 6
(2)
This calculation implies that flow rates commonly used with
this application device are far below those associated with the on-
set of turbulence, and could probably be increased 100-fold (e.g.,
by application of pressure) without inducing flow-related turbu-
lence.
Test applications with fast green dye dissolved in water can be
delivered either into a test dish or the actual recording chamber un-
der direct microscopic observation to ensure that flow is present
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prior to starting the experiment. This will give a good measure of
the force and speed of drug application and the duration of the
fixed delay, and ensures that there are no plugs or leaks. Air leaks
around the pipette tip appear as bubbles between the device and the
solenoid, which significantly slow the application by destroying the
“water hammer” created by the solenoid. Bubbles elsewhere are
less problematic but can inhibit the rapid change of drug solutions.
The dye trial also shows how long it takes to clear a drug solu-
tion from the line. Depending on the lengths of tubing involved,
the flow of drug should be started about 10 s prior to application
and allowed to continue for 5–10 s after the solenoid reopens. To
wash out any residual drug and to maintain constant flow of fluid
without wasting drug/saline solutions, we let distilled water flow
through the apparatus at other times. The constant suction from
the dish (due to the Bernoulli effect) ensures that no water enters
the recording bath solution, though enough time must be allowed
for drug to fill the line prior to drug application. Alternatively, the
tubing can be charged with saline and both drain and source tubes
can be clamped shut between drug applications (so there is no
drainage of solution from the dish).
Cell culture and transfection
Mouse L929 cells (American Type Culture Collection, Rockville,
Md., USA) were grown in Dulbecco’s modified Eagle’s medium
(DMEM) with 10% horse serum and 100IU/ml penicillin and
100 µg/ml streptomycin at 37°C in 5% CO2/95% air. Full-length
cDNAs encoding bovine α1, β1 and γ2S [28] subcloned individual-
ly into pCMVneo expression vectors, and the cDNA encoding
Aequorea victoriagreen fluorescent protein (gfp, generously pro-
vided by Dr. Martin Chalfie) [3], subcloned into pCMVneo as a
marker of transfection were transfected into L929 cells in a ratio
of 1:1:1:3 (3 µg of each of the GABAR subunits and 9µg of
pCMV-gfp), as previously described [2]. A total of 18µg of DNA
was added per 60-mm dish in 0.5 ml of transfection buffer. Cells
were incubated for 4–6 hours in 3% CO2 at 37°C and then
shocked for 30 s with 50% glycerol/transfection buffer solution.
The following day, transfected cells were treated with DNase I,
and replated onto gridded 35-mm plates (Mecanex) for subsequent
identification during scoring and electrophysiological recording.
Using fluorescence micrography with fluorescein filters (Chroma
High-Q FITC, no. 41012, excitation 460–500 nm, emission
510 nm long pass), the positions of positive cells on the grid were
drawn for subsequent electrophysiological recording within
48–60 h after transfection [2].
Electrophysiological recording
Prior to recording, the DMEM medium was replaced with multiple
washings of external recording medium containing (in mM): 142
Fig. 1 A Schematic of the
multipuffer U-tube device.
B Simplified plan of a record-
ing set-up including a multi-
puffer for drug application.
See Materials and methods for
details of implementation& / fi g. c :
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NaCl, 8.1 KCl, 6 MgCl2, 10 glucose, 10 4-(2-hydroxyethyl)-1-pi-
perazineethanesulfonic acid (HEPES) (pH 7.4). Recording pipettes
contained (in mM): 153 KCl, 1 MgCl2, 5 ethylenebis(oxo-
nitrilo)tetraacetate (EGTA) and 10 HEPES (pH 7.3). These solu-
tions produce a Cl– equilibrium potential (ECl) of approximately
0 mV and a K+ equilibrium potential (EK) of –75 mV. To quantify
the response time of the drug application system, increasing con-
centrations of K+ were made by serial dilution of the recording
medium with 158 mM KCl, without changing solution osmolality.
Solutions with increasing K+ concentration were applied to an
“open electrode” recording in constant-current mode to record the
change in electrode tip potential. Most GABAA receptor experi-
ments were performed in the whole-cell configuration in voltage-
clamp mode at –75mV using an Axopatch 200A amplifier. Whole-
cell currents were filtered at 2 kHz and digitized on line by a Lab-
master Tl-40 ADC at 200 Hz and recorded using Axotape 2.0 soft-
ware (Axon Instruments). Peak currents were measured from digi-
tized records. For single-channel recordings, “outside-out” patches
were formed using standard techniques [10]. Single-channel cur-
rents were digitized on-line at 20 kHz using Axotape 2.0 software
and later analyzed using IPROC (Axon Instruments), PRISM
(Graphpad) and software developed in our laboratory [19]. All
chemicals and drugs were obtained from Sigma.
Results
Response time course for multipuffer application
Prior to recording receptor-elicited currents, we wished to
quantify the rate of solution change and the delay between
solenoid actuation and solution change. To eliminate the
role of membrane capacitance, we measured the change in
potential of an open electrode tip (recorded in current-
clamp mode, with standard intracellular pipette solution,
see Materials and methods) in response to a step change in
K+ concentration from that of the extracellular recording
medium (8 mM) to 158 mM KCl, the maximum K+ con-
centration possible without changing solution osmolality.
The time course of the rising phase of a step change from
8 mM to 158 mM K+ is shown in Fig. 2A. The 10% to
90% rise time in this case was 57.4 ms (mean ±
SEM = 54.4±4.96 ms, n = 5, see Table 1). The time for a
“complete” transition (at least 98% of the maximal volt-
age change) was 101.4±9.4 ms (n = 5), which reflects the
time required for a complete solution change. The time
course of the electrode tip potential change was well fit
with a single exponential decay with a time constant, τ,
(defined as 1–1/e of the complete transition time) of
23±3 ms (n = 5). The delay from the onset of solenoid clo-
sure to the onset of the voltage change at the electrode tip
was very consistent (118±3.3 ms). On a slower time scale
(Fig. 2B), the square shape of this voltage response indi-
cated that the K+ concentration and flow characteristics re-
mained fairly constant during the application. The stability
of the plateau response implied an adequate “concentra-
tion clamp” of the perfused region. Time characteristics of
the falling phase of the K+ step application are also given
in Table 1; however, these should be viewed as “best case”
characteristics for brief (2–3 s) applications. With longer
applications, the applied drug may accumulate in the me-
dium and diluted drug will wash past the cell or patch
when the application ends, making the time course of the
concentration change indeterminate.
Although the ion gradient at the electrode tip was not
restricted by a membrane (and hence not predicted by
the Nernst equation), the magnitude of this potential
Table 1 Rise and fall time characteristics of multipuffer applica-
tion. (n = 5)& / t bl . c : & t bl . b :
Variable Rising phase Falling phase
Mean SEM Mean SEM
Delay (ms) 118.1 3.33 93.7 7.1
Amplitude (mV) 3.09 0.05 3.43 0.05
Transition time (ms) 101.4 9.4 136.3 6.29
Rise time (10–90%) 54.4 4.96 75.5 54.7
τ [ = (1–1/e) · rise time] 23.0 2.98 54.7 3.09
& / t bl . b :
Fig. 2A–C Voltage responses of an open electrode tip to applica-
tion of solutions containing different concentrations of K+. A Time
course of the rising phase of a step change from 8 mM to
158 mM K+. The 10% to 90% rise time was 57.4 ms. B Voltage re-
sponse to a pulse step change from 8 mM to 158 mM K+ on a
slower time scale. The “square” shape of this response indicates
that the K+ concentration remained fairly constant during the ap-
plication. C Plot of the amplitude of the voltage response of an
open electrode to increasing concentrations of K+. Each point rep-
resents the mean of three responses; SEM error bars fall within
the symbol diameter& / fi g. c :
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should be a function of K+ concentration. Solutions with
varying K+ concentrations were made by diluting the
158 mM KCl stock solution with the extracellular re-
cording medium, yielding K+ concentrations of 8, 16, 32,
48, 96, and 158 mM, with constant osmolality. Peak volt-
age responses for each K+ concentration are plotted in
Fig. 2C. Although these potential shifts were small
(maximum 3.09±0.05 mV for the 158 mM KCl solution)
and there was a flow-related voltage offset of 0.64 mV,
the amplitude of the tip potential varied linearly with K+
concentration (slope of 14.2µV/mM K+, r = 0.996).
Whole cell GABAA receptor currents
Next we wished to determine whether the multipuffer
device was useful in characterizing the pharmacological
properties of recombinant GABAA receptor (GABAR)
currents. Whole cell currents were recorded from L929
cells 48 h after transfection with α1β1γ2S GABAR
cDNAs. Due to the symmetrical Cl– concentrations in-
side and outside the cell (after exchange of intracellular
ions with the pipette medium), GABAR currents were
inward (downward) when the cell was voltage-clamped
at –75 mV. Currents elicited by GABA (1µM, Fig. 3A,
Fig. 3A, B Whole-cell currents in L929 cells transfected with bo-
vine α1β1γ2S GABAA receptor cDNAs elicited by GABA and
pharmacological agents. A Currents elicited by GABA (1µM)
alone (1st., 3rd and 5th traces) or in the presence of diazepam
(DZ, 0.1µM, 2nd trace) or pentobarbital (PB, 150µM, 4th trace).
B Currents elicited by GABA (10µM) alone (1st, 3rd and 5th
traces) or in the presence of bicuculline (BC, 10 mM, 2nd trace)
or picrotoxin (PTX, 10 mM, 4th trace). All currents were recorded
in the whole-cell configuration at –75 mV.& / fi g. c :
Fig. 4A, B Concentration/re-
sponse relationship for L929
cells transfected with α1β1γ2S
GABAA receptor cDNAs.
Whole-cell recordings were
carried out at –75 mV.
A Sequential applications of
increasing concentrations of
GABArevealed threshold
currents at 1µM GABA and
saturating currents at 100µM
GABA. B A plot of peak
currents versus GABA concen-
tration reveals an EC50 of
10.4µM (n = 13) and a Hill
slope of 1.30. C A plot of
normalized peak currents
versus GABA concentration
shows no change in EC50
(12.2µM) or Hill slope (1.27)
& / fi g. c :
traces 1, 3 and 5) were enhanced by the coapplication of
diazepam (DZ, 0.1µM, second trace) or pentobarbital
(PB, 150 µM, fourth trace), as expected for receptors
containing these subunits [17]. Similarly, currents elicit-
ed by GABA (10µM, Fig. 3C, traces 1, 3 and 5) were
inhibited by bicuculline (BC, 10µM, second trace), a
competitive antagonist at the GABA-binding site, or by
picrotoxin (PTX, 10µM, fourth trace), a non-competi-
tive GABAR antagonist [23, 24, 30].
Sequential applications of increasing concentrations
of GABA (Fig. 4A) during whole-cell recordings re-
vealed threshold currents at approximately 1µM GABA
and saturating currents at 100µM GABA. A plot of peak
currents versus GABA concentration revealed an EC50 of
10.4µM (Fig. 4B, n = 13), with increasing variability of
amplitude at larger GABA concentrations due to the
variable maximal current amplitude (hence variable
number of GABAR channels expressed) in each cell.
When the responses of each cell were normalized to the
maximal peak current (at any concentration) for that cell
(Fig. 4C), the variability of maximal amplitude was
eliminated, while the EC50 was virtually unchanged
(12.2 µM). For both actual and normalized peak current
concentration/response curves, there was a Hill slope
greater than 1.0 (1.30 for actual currents, 1.27 for nor-
malized data), suggesting that more than one GABA-
binding site with positive cooperativity may be involved
in channel opening.
Activation and desensitization of GABAR currents
The validity of the concentration/response relationship to
GABA may depend on how rapidly the currents are acti-
vated by the arrival of GABA-containing solutions; if
this arrival is gradual, significant desensitization may oc-
cur and the peak response may be blunted [5]. To assess
the rates of activation and desensitization for these re-
ceptors, we initially examined the time course of onset of
GABAR currents for a single cell (Fig. 5). In Fig. 5A,
currents elicited by increasing concentrations of GABA
were aligned at the time point of solenoid closure. As
GABA concentration increased, the slope of current on-
set increased, with an initial delay and an “S-shaped”
initial rising phase. These same responses were normal-
ized to the maximal current and then plotted on an ex-
panded time scale (Fig. 5B). Since the distance from the
T-tube outlet and the cell was constant, the relatively lon-
ger delays before the onset of current at lower GABA
concentrations and the sigmoidal shape of current onset
appear to be a function of receptor activation, and likely
reflect the combination of GABA association and disso-
ciation rates, cooperativity between GABA-binding sites,
and channel opening rates (see below). At GABA con-
centrations up to 300µM, the onset of GABA currents
was significantly slower than the rise time for the
stepped KCl gradient to an open electrode (leftmost
trace, Fig. 5B), implying that the rate of solution applica-
tion was not limiting for the development of current at
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Fig. 5A–C Currents elicited by increasing concentrations of
GABA in a single L929 fibroblast transfected with α1β1γ2S
GABAA receptor cDNAs. A Whole-cell currents, aligned at the
time point of solenoid closure, showing an increased rate of on-
set and faster desensitization with increased GABA concentra-
tion. B The same responses normalized to the maximal current
and plotted on an expanded time scale. Symbolsfor each concen-
tration are noted in the figure. At GABA concentrations up to
1 mM, the onset of GABA currents was significantly slower than
the rise time for the step KCl gradient to an open electrode (left-
most trace). C Early desensitization of the response at concentra-
tions between 10µM and 1 mM during continued application of
GABA. Currents were normalized to the peak current for each
concentration at the onset of desensitization. Desensitization was
concentration dependent but approached a maximal rate at
100–300µM. The time course of desensitization was modeled by
a single exponential decay with time constants as noted in the
figure& / fi g. c :
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these concentrations. The time to peak for 1 mM GABA
applications was approximately 75 ms (in this cell),
somewhat less than the time for “complete” solution
change for a K+ gradient at an open electrode (101 ms)
and approaching the 10–90% rise time (54 ms).
Early desensitization of the response was not ob-
served at GABA concentrations below 10µM (Fig. 5A).
At concentrations between 10µM and 1 mM, an early
phase of desensitization during continued application of
GABA was observed to occur in this cell. When normal-
ized to the peak current obtained for each concentration
at the onset of desensitization (Fig. 5C), current desensi-
tization was concentration dependent but approached a
maximal rate at 100–300µM. The time course of desen-
sitization could be adequately modeled by a single expo-
nential decay with time constants varying from 4.3 s for
1 mM GABA to 290 s for 10µM GABA. The rates of
desensitization were highly variable among cells, howev-
er, and a detailed examination of desensitization time
course was felt to be beyond the scope of the current
study. We did not observe the rapid phases of desensiti-
zation (with time constants of the order of tens to several
hundred milliseconds) seen with excised membrane
patches and ultrarapid drug application techniques [5,
12].
We focused instead on the time course of onset of GA-
BAR currents, which was more consistent among cells
under these conditions. When normalized to the maximal
current, the initial rate of development of GABAR cur-
rents was remarkably uniform at concentrations compris-
ing the sigmoidal portion of the concentration/response
curve (1–300µM, Fig. 6A). With 1 mM GABA applica-
tions, the rate of current onset was faster than for
300 µM; however, the peak current amplitude was often
smaller than at 100 or 300µM, implying some desensiti-
zation of the response prior to the development of peak
current. These currents were therefore not included in the
evaluation of the initial time course. The time course of
currents elicited by increasing concentrations of GABA,
I(t), could be fit with the sum of two exponential associa-
tion curves, of the form I(t) = A·[1–exp(–t/τ1)]–B·[1–exp
(–t/τ2)]. The second exponential component with a nega-
tive coefficient was necesary to account for the concen-
tration-dependent delay and sigmoidal rise of the initial
slope of the response, which was most obvious for the
10 µM applications (Fig. 6A). The exponential activation
coefficients (kact = 1/τ1) corresponding to the linear por-
tion of the concentration/response relationship (from
3 µM to 100 µM) were directly proportional to the
GABA concentration with a slope of 1.14×105 M–1 s–1
(r2 = 0.98), providing a rough estimate of the minimum
opening rate of the receptor as a function of GABA con-
centration (Fig. 6B).
Single channel GABAA receptor currents
To assess the utility of the multipuffer device for single-
channel recordings, we recorded single-channel currents
elicited by 1µM GABA in outside-out patches (Fig. 7).
Applications of increasing concentrations of GABA re-
sulted in concentration-dependent increases in channel
opening frequency and burst duration and, in multichan-
nel patches (Fig. 7A), it increased the frequency of si-
multaneous openings of multiple channels. Kinetic anal-
ysis showed that single-channel currents from one such
“outside-out” membrane patch demonstrated characteris-
tics similar to those seen with this combination of sub-
unit subtypes in prior recordings from this laboratory
(1,24) using single-pipette GABA application, with a
mean open time of 3.94 ms. Approximately 85% of
openings occurred in bursts lasting an average of 10 ms
with about two openings per burst (n = 277 openings).
Figure 7B shows a sample tracing of single-channel cur-
rents elicited by GABA (1µM) at multiple time scales to
demonstrate the structure of burst openings. A histogram
of current amplitudes for a small number of openings
Fig. 6A, B Initial GABA receptor current development normalized
to the maximal current for each cell (n = 5) at GABA concentra-
tions ranging from 1µM to 300µM. Symbolsfor each concentra-
tion are noted in the figure. The initial phase of currents elicited
by increasing concentrations of GABA was fit with the sum of two
exponential association curves. B The exponential activation coef-
ficients (kact = 1/τ1) corresponding to the linear portion of the con-
centration/response relationship (3–100µM) were plotted against
GABA concentration. A linear relationship was observed with a
slope of 1.14×105 M–1 s–1 (r2 = 0.98), which estimates the mini-
mum opening rate of the receptor as a function of GABA concen-
tration& / fi g. c :
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(Fig. 7C) shows a single main conductance state of ap-
proximately 26 pS.
Discussion
The whole-cell pharmacology and single-channel char-
acteristics of α1 β1 γ2S GABAR currents obtained using
the multipuffer device were consistent with prior charac-
terizations of this receptor isoform, measured in our lab-
oratory using the single “puffer” pipette system [1], but
use of the multipuffer system enabled a more complete
pharmacological characterization to be performed for
each cell or patch. The system was “quiet” enough to al-
low single-channel recordings at high amplifier gain
(100 mV/pA). We did not analyze a large number of
channel openings for detailed kinetics or the presence of
subconductance states, as these have been studied in de-
tail previously in our laboratory [1].
Application of KCl solutions to an open electrode
demonstrated solution change with an exponential time
constant, τ, of 27 ms and 10–90% rise time of 54 ms. Al-
though this rise time was significantly faster than the rate
of rise for the highest concentrations of GABA tested
(1 mM), for the pharmacological data derived from this
system to be meaningful, the rate of drug application
must be fast enough to exceed the activation rate and
minimize early desensitization of the receptor under
study. With the advent of ultrarapid application devices
[5, 12, 20, 21, 29], the results of the current study can be
compared to those measured using techniques that offer
improved kinetic resolution, though less pharmacologi-
cal flexibility. The fastest time to peak current in our re-
cordings was approximately 75 ms (for 1 mM GABA ap-
plications), approaching the rate of solution change. This
was far slower than the maximal rise time of 0.5 ms for
GABA concentrations of 1–10 mM observed by Twyman
[29], using an ultrafast ligand exchange system (ex-
change time of 0.1 ms) and mouse cortical neuron patch-
es containing 5–25 channels (though at low GABA con-
centrations, the rise time was about 2 s, similar to our re-
sults). Similarly, using outside-out patches Maconochie
and Knight [20] observed a rise time of 0.4 ms, and
Jones and Westbrook [12] measured fastest rise times of
about 1.8 ms, while Puia et al. [25] observed the fastest
time to peak, of the order of 0.4 ms in nucleated patches
from cerebellar granule neurons. However, Gingrich et
al. [8], using a two-barrel control/GABA pipette system
with solution change within 1–2 ms, recorded a fastest
time to peak of 30 ms with 1 mM GABA application for
both α1 β2 γ2S and α3 β2 γ2s receptors in whole-cell re-
cordings. The maximal rate of rise of GABA currents is
Fig. 7A, B Single-channel
currents elicited by GABA
(1 mM) in “outside-out” mem-
brane patches from an L929
cell transfected with α1 β1 γ2S
GABA receptor subunits,
voltage-clamped at –75 mV.
A Prolonged application of
0.3µM GABA (a) and 1µM
GABA (b) to an outside-out
patch containing multiple
channels (at least 4). B Current
traces of single-channel open-
ings of α1 β1 γ2S channels at
3 time scales. Tracesb and c
are expanded segments from
tracesa and b, respectively.
C Amplitude histogram of
single-channel current ampli-
tudes showing a single conduc-
tance state of 26 pS in bovine
α1 β1 γ2S channels& / fi g. c :
approximately tenfold slower than those used in other re-
cent kinetic models [5, 8, 21, 29]. Gingrich et al. [8]
were able to account for the activation and desensitiza-
tion rates observed to occur in whole-cell currents using
a two binding site gating model developed in our labora-
tory to account for intraburst and extraburst neuronal sin-
gle-channel kinetic properties, with whole-cell simulated
currents first-order filtered at 12 Hz (–3 db) to account
for the limitations of the response time. They found that
different α subunit subtypes resulted in marked differ-
ences in channel activation rates at the whole-cell level,
and modeled the α1-containing-receptors with an on-rate
(k1) of 2.1×106 M–1 s–1 and off rate (k–1) of 14.6 s–1, or a
tenfold faster off rate and 20-fold faster on-rate. Celen-
tano and Wong [5] obtained the best fit to their data with
an on-rate (k1) of 2.97×106 M–1 s–1 and an off-rate (k-1)
of 43.1 s–1, though their measured off-rate with a time
constant of 230 ms predicted a dissociation time constant
of 4.35 s–1. Both Maconochie et al. [21] and Twyman
[29], while not proposing specific rate constants, found a
maximum channel opening rate of 6000 to 6500 s–1. The
most likely explanation for the slower activation rates
seen in our recordings is the “low-pass filtering” result-
ing from the rate of solution application and recording in
whole-cell configuration, as noted by Gingrich et al. [8].
However, it should be stressed that meaningful rate con-
stants cannot be obtained from whole-cell recordings
with the solution exchange rates observed with multi-
puffer application.
We observed concentration-dependent desensitization
of GABAR currents in the continued presence of agonist,
which could be modeled with a single exponential decay
with time constants ranging from 4.3 s for 1 mM to al-
most 300 s for 10µM GABA. These time constants were
similar to those observed by Frosch et al. [7] using single
“puffer” micropipette application onto cortical neurons
in culture, and the desensitization rates observed by
Gingrich et al. [8] with a rapid application system onto
transfected HEK293 cells (though they did not model
these rates with exponential functions per se). Several
laboratories [5, 12, 21], using ultrarapid (submillisecond)
application systems onto macropatches, have demon-
strated rapid phases of desensitization of GABAR cur-
rents with exponential decay time constants of the order
of 10–20 ms, which might not be detected by multipuffer
application. Celentano and Wong [5], using a multibarrel
application system with solution change in under 1.5 ms
to apply GABA solutions to outside-out macropatches,
noted three phases of desensitization with time constants
of 15.4, 207 and 1370 ms. However, these rapidly desen-
sitizing states become prominent only at very high
GABA concentrations (300µM to 1 mM [5]), and were
not seen at the linear portion of the concentration/re-
sponse curve, where much of the allosteric pharmacolo-
gy of the receptor occurs [18, 26]. Moreover, the fastest
τ for desensitization only comprised 15% of the desensi-
tization at 300µM and 20% at 1 mM. We did not ob-
serve the rapid phases of desensitization (with time con-
stants of the order of tens to hundreds of milliseconds)
1088
thus not only a function of the solution exchange rate,
but depends heavily on the recording technique (whole-
cell versus single-channel or macropatch). The slower
time to peak in whole-cell recordings compared with that
seen in isolated membrane patch recordings is probably
related to the sequential activation of spatially distributed
channels and the delays in diffusion associated with cell
adherence to the dish. The wavefront of drug solution
moving at 10 cm/s over a cell of 50µm diameter will
take at least 0.5 ms to wash over the cell, not accounting
for areas where diffusion is more limited. For patch r -
cording, the number and spatial distribution of channels
are far smaller, and solution exchange rate becomes
more critical. Maconochie and Knight [20] have calcu-
lated the theoretical limit to the speed of solution change
(based on diffusion calculations) to be approximately
0.2 ms, which may be the limiting factor for high con-
centration applications to excised patches. At low GABA
concentrations and whole-cell recordings, results with
the multipuffer system and ultrarapid techniques are
quite similar. While the speed of multipuffer application
is insuffficient for ultrarapid kinetic studies of GABAR-
containing macropatches or single channels, it appear  to
be fast enough for meaningful whole-cell pharmacology
at GABA concentrations below 300–1000µM as well as
“steady-state” single-channel recordings.
The time course for GABAR current development in
our experiments could be modeled as the sum of two ex-
ponential association functions. The time constant for
current development should be a complex function of the
association and dissociation rates for GABA, the rate of
channel opening after binding of GABA, and the rates of
exit to desensitized states. Although prior models from
our laboratory based on single-channel burst kinetic data
have included two GABA-binding steps and distal closed
states to model intraburst closures [19, 31], the simplest
associated model that takes into account the binding of
ligand to receptor and subsequent opening of the ligand-
ed channel takes the following form:
R + A ⇔ RA⇔ RA*
where R refers to the receptor, A to agonist (GABA), RA
to the liganded receptor and RA* to the open conforma-
tion of the channel (assuming, for the moment, a single
binding site, a single open state, and no desensitized
states [11]). Assuming further that channel opening r te
is fast relative to binding, the time course of current acti-
vation will be a function primarily of the binding rate,
given by the equation I(t) = A (1–exp({(k 1[A] + k–1)t} ).
The dissociation rate, k–1, can be inferred from the disso-
ciation constant for the complex at equilibrium, which
is determined empirically from the observed EC50
(12.2µM). While the true activation constants cannot be
determined from the data available, activation rates con-
sistent with the observed activation coefficient of
1.14×105 M–1 s–1 and Kd of 12.2 µM could be modeled
with a relatively slow off-rate, k–1, of 1.5 s–1 and an asso-
ciation rate, k1, of 1.23×105 M–1 s–1. These numbers are
k1
k–1
seen with ultrarapid drug application techniques and
macropatch recording [5, 12]. In our whole-cell record-
ings, we have sometimes noticed a diminution of current
peak amplitude at supramaximal GABA concentrations
(producing a “U-shaped” concentration/response rela-
tionship, data not shown). In these cases, subsequent ap-
plications of lower concentrations of GABA produced
smaller responses, implying that desensitization of some
of the receptors had occurred. Application of high con-
centrations of GABA may accelerate transitions to a de-
sensitized state from which recovery is slow, of the order
of minutes. This desensitization of the response presum-
ably occurred during the time of solution equilibration
(i.e., the first 50–100 ms of application), before the peak
current was expressed. This would be consistent with a
desensitization time constant shorter than 100 ms. Celen-
tano and Wong [5] noted that preapplication of 30µM
GABA eliminated the fast phase of current desensitiza-
tion, blunting the response, while a brief wash after com-
pletion of the rapid phase of desensitization (to 1 mM
GABA) again decayed with biphasic kinetics, consistent
with the remaining (non-desensitized) receptors being
capable of interconversion between desensitized states.
Although rapid desensitization rates (and the associated
transient peaks currents) might have been obscured in
our system by the relatively slower rate of drug onset
(10–90% rise time of 54 ms), the GABARs that desensi-
tized prior to channel opening are thus part of the same
population of channels that subsequently open and de-
sensitize more slowly. While the major effect of this
“lost phase” of desensitization is a blunting of currents
elicited by higher concentrations of GABA, resulting in a
modest leftward shift of the EC50 [5], the basic pharma-
cology of the receptor and the kinetics of currents elicit-
ed by lower concentrations of GABA are not different
from those seen with ultrarapid techniques and macro-
patch recording. Ultrarapid application systems are im-
portant for evaluating the kinetics of GABAR opening
and desensitization in single-channel or multichannel
patch recordings at high GABA concentrations, simulat-
ing conditions that may occur at some inhibitory synap-
ses [6].
The multipuffer is a device for applying limited quan-
tities of drug solutions rapidly to small areas of a cell
culture dish for use in electrophysiological recordings.
Unmodified U-tube techniques and multibarrel large-di-
ameter (200µm) pipette applications (e.g., Celentano
and Wong [5]) used for ultrarapid drug application allow
many drugs to be used during the course of an experi-
ment, but bathe the entire culture dish with drug solu-
tion, potentially leading to desensitization of receptors
on other cells and necessitating another source of saline
superfusion and an additional drain for the drug to be re-
moved from the medium. Glass micropipette “puffers” or
multibarrel pipettes pulled to a fine tip (10–20µm) can
apply small amounts of a single drug concentration per
pipette barrel to restricted areas of the culture dish.
These techniques are excellent for applying small vol-
umes of precious reagents (e.g., enzymes or rare/expen-
sive drugs). However, each drug concentration comes
from a puffer pipette located at a different angle to the
cell/patch from which recordings are being made, or
from an opening of different size and position on a
multibarrel pipette, hence the response times and delays
c nnot be identical. The multipuffer device allows: (1)
close proximity to the cell of interest (within
50–100µm), without obscuring the visual field, (2) brief
applications of small volumes, minimizing desensitiza-
tion of receptors on other cells, (3) a relatively rapid rate
of application, and (4) suction of drug solutions back in-
to the tip after application due to the Bernoulli effect,
without need of an additional drain or superfusion. In ad-
dition: (1) the pipette tip can remain close to the cell or
patch throughout the recording, (2) the rate of solution
application can be controlled by adjusting the height of
the drug reservoirs and the micropipette tip diameter, (3)
new drug solutions can be mixed and used immediately,
and (4) the system is relatively simple, low in cost and
easy to use and maintain.
Limitations of the multipuffer device include: (1) it is
ot suitable for “precious” reagents (enzymes, etc.) that
cannot be prepared in large volumes for dilute applica-
tion, (2) “layered” drug application (i.e., preapplication of
one drug or concentration followed immediately by a sec-
ond drug or a combination of two drugs) would require a
econd multipuffer, and (3) it is not suitable for studies of
receptors or channels that require applications on a sub-
millisecond time scale. Other practical problems include
bubbles in the tubing, leakage of air or drug solutions,
and plugging of the glass pipette tip, particularly in re-
cording solutions with a lot of cellular debris, though this
may be minimized by positive perfusion with recording
saline during periods between drug applications.
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